All Congress Publications
Boehringer Ingelheim is committed to sharing knowledge with the healthcare community. Follow the links and find a variety of downloadable resources and articles with information related to Oncology.
1 - 10 of 45 results
Publications
Gathering our presentations, posters, abstracts, and publications, this educational resource offers materials across topics of interest in oncology. Explore the current topics below and revisit regularly to access the latest materials.
Poster
DAREON®-NEC-1: Phase III trial of first-line (1L) obrixtamig plus carboplatin and etoposide (SoC) vs SoC in patients with delta-like ligand 3 (DLL3)-positive extrapulmonary neuroendocrine carcinoma (epNEC)
Author(s): Vandamme et al.
DAREON®-9: A Phase Ib open-label dose escalation/confirmation study of obrixtamig (BI 764532) plus topotecan in patients with extensive-stage small cell lung cancer (ES-SCLC) ‒ topotecan use analysis
Author(s): Wermke et al.
Updated Phase Ia results with systemic STING agonist BI 1703880 plus ezabenlimab in patients with advanced solid tumors
Author(s): Harrington et al.
DAREON®-Lung-1: Phase III trial of first-line obrixtamig plus standard of care (atezolizumab, carboplatin, and etoposide) versus standard of care in ES-SCLC
Author(s): Leal et al.
Analysis of delta-like ligand 3 (DLL3) expression levels and characteristics of patients with advanced extrapulmonary neuroendocrine carcinomas (epNECs) from an ongoing Phase I trial
Author(s): Gambardella et al.
DAREON®-8: updated efficacy and safety from a Phase I dose-escalation/expansion trial of first-line obrixtamig plus chemotherapy and atezolizumab in extensive-stage small cell lung carcinoma
Author(s): Peters et al.
Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas of genitourinary origin with high or low DLL3 expression: results from an ongoing Phase I trial
Author(s): Navarro-Gorro et al.
DAREON®-7: Phase I open-label dose-escalation/-expansion study of first-line obrixtamig (BI 764532) plus platinum-doublet chemotherapy in patients with DLL3-positive neuroendocrine carcinomas
Author(s): Chauhan et al.
Ezabenlimab (BI 754091) and induction mDCF (modified docetaxel, cisplatin, and 5-fluorouracil) followed by adaptive chemoradiotherapy in patients with stage III squamous cell anal carcinoma: final results of the Phase II INTERACT-ION study
Author(s): Kim et al.
An open-label, Phase Ib trial to assess the safety and efficacy of SIRPα monoclonal antibody BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with head and neck squamous cell carcinoma (NCT06806852)
Author(s): Laban et al.